1 History of transfusion

Transfusion developed from early experimental attempts to replace or modify blood in the body into a highly regulated medical therapy. Its history reflects advances in physiology, microbiology, immunology, and laboratory medicine. Over time, transfusion shifted from a hazardous procedure of uncertain benefit to a targeted treatment using specific blood components.

1.1 Early blood transfer attempts

The earliest recorded ideas about blood transfer emerged from speculation about blood as a vital fluid. In the 17th century, investigators in Europe performed animal-to-animal and animal-to-human transfusion experiments, often with limited understanding of circulation or compatibility. Some procedures were intended to treat illness by transferring qualities believed to be present in blood, but outcomes were inconsistent and frequently dangerous.

1.2 Development of blood typing

The modern era of transfusion began with the discovery of blood group systems. The identification of the ABO blood groups showed that blood was not universally interchangeable. Later recognition of the Rh system further improved safety by explaining additional incompatibilities. These discoveries made it possible to match donors and recipients more accurately and greatly reduced severe reactions.

1.3 Advances in storage and screening

As transfusion practice expanded, methods were developed to preserve blood outside the body for longer periods. Anticoagulants and refrigeration allowed collection and storage for later use, which made blood banks possible. Screening for infectious agents, along with improved donor selection and laboratory testing, reduced the risk of transmitting disease. Component separation also became important, allowing one donation to serve multiple patients.

1.4 Modern transfusion medicine

Current transfusion medicine emphasizes precision, traceability, and patient safety. Rather than giving whole blood routinely, clinicians often transfuse only the required component. Decisions are guided by laboratory values, clinical status, and anticipated benefit. The field now includes immunohematology, donor medicine, blood banking, hemovigilance, and conservation strategies designed to use blood resources efficiently.

2 Blood and blood components

Blood transfusion may involve whole blood or individual components separated for specific therapeutic purposes. Component therapy allows treatment to be tailored to the patient’s needs while limiting unnecessary exposure to other blood elements. Each product has distinct properties, indications, and storage requirements.

2.1 Whole blood

Whole blood contains red blood cells, plasma, platelets, and coagulation factors in their natural proportions. It can be useful in situations requiring rapid replacement of blood volume and oxygen-carrying capacity, especially in severe hemorrhage where component therapy is not immediately available. In many settings, however, whole blood is less commonly used than separated components.

2.2 Red blood cells

Red blood cell concentrates are used primarily to restore oxygen delivery. They are the most frequently transfused component in many health systems. Indications include symptomatic anemia, acute hemorrhage, and conditions in which the body cannot maintain adequate tissue oxygenation. The main therapeutic effect is increased hemoglobin concentration and oxygen transport.

2.3 Platelets

Platelet transfusion is used to prevent or treat bleeding caused by low platelet counts or platelet dysfunction. It is common in patients with hematologic disorders, those undergoing intensive chemotherapy, and individuals with significant thrombocytopenia. Platelets are also given before invasive procedures when bleeding risk is elevated.

2.4 Plasma

Plasma is the liquid portion of blood and contains clotting factors, proteins, and other soluble substances. Transfused plasma is used to correct multiple coagulation factor deficiencies, particularly when bleeding is present or when urgent reversal of coagulopathy is needed. It also serves as a source material for further processing into specialized products.

2.5 Cryoprecipitate

Cryoprecipitate is a concentrated plasma fraction rich in fibrinogen and certain clotting proteins. It is used when fibrinogen levels are low and bleeding risk is significant. Because of its composition, it can be helpful in specific bleeding disorders and in massive transfusion settings where fibrinogen depletion may occur.

2.6 Fractionated products

Fractionated blood products are manufactured from plasma using industrial separation techniques. These include purified clotting factors, albumin, immunoglobulins, and other protein preparations. Such products are used for targeted therapy and may provide advantages in potency, standardization, and reduced volume compared with untreated plasma.

3 Indications

The need for transfusion depends on the patient’s condition, laboratory values, bleeding risk, and anticipated response. In many cases, transfusion supports a failing physiologic system rather than treating the underlying disease directly. Clinical judgment is essential because not every abnormal test result requires transfusion.

3.1 Acute blood loss

Acute hemorrhage is one of the most urgent indications for transfusion. Trauma, surgery, gastrointestinal bleeding, and obstetric bleeding can cause rapid loss of circulating volume and oxygen-carrying capacity. Transfusion helps restore perfusion, maintain oxygen delivery, and support hemostasis while the source of bleeding is treated.

3.2 Anemia

Red blood cell transfusion may be used in anemia when low hemoglobin levels are associated with symptoms or when oxygen demand exceeds supply. Common symptoms include fatigue, dyspnea, dizziness, and chest discomfort. The decision to transfuse depends on the cause of anemia, the patient’s clinical state, and the pace at which the blood count has fallen.

3.3 Thrombocytopenia and bleeding disorders

Low platelet counts can lead to spontaneous or procedure-related bleeding, especially when counts are severely reduced. Platelet transfusion is often used to reduce this risk. Inherited or acquired bleeding disorders may also require transfusion support when platelet function is impaired or when bleeding cannot be controlled by other means.

3.4 Coagulation factor deficiencies

Deficiencies of clotting factors may result from liver disease, dilutional coagulopathy, disseminated consumption, or specific inherited disorders. Plasma, cryoprecipitate, or factor concentrates can be given to correct these abnormalities. The choice of product depends on the factor involved and the urgency of treatment.

3.5 Support during surgery and trauma

Transfusion is frequently used during major surgery and traumatic injury to replace blood loss and maintain hemodynamic stability. In these settings, rapid assessment of blood loss, coagulation status, and transfusion needs is critical. Balanced replacement of red cells, plasma, and platelets may be required when bleeding is severe.

3.6 Specialized clinical uses

Some patients require transfusion for less common reasons, such as exchange transfusion, neonatal support, or management of certain hematologic diseases. In selected immunologic or metabolic conditions, transfusion products may be chosen for their specific protein or cellular content. These uses are generally guided by specialized protocols.

4 Compatibility and testing

Compatibility testing is essential to reduce the risk of transfusion reactions. The process identifies blood group characteristics, detects unexpected antibodies, and verifies that the selected unit is appropriate for the recipient. Careful laboratory procedures are a central part of transfusion safety.

4.1 ABO blood group system

The ABO system classifies blood based on antigens present on red blood cells and corresponding antibodies in plasma. Incompatible ABO transfusion can cause rapid and severe hemolysis. For this reason, ABO matching is one of the most important elements of pretransfusion testing.

4.2 Rh blood group system

The Rh system, especially the D antigen, is a major source of incompatibility after ABO. Rh-negative recipients can form antibodies if exposed to Rh-positive blood, which may complicate future transfusions. Rh matching is particularly important in patients likely to need repeated transfusion and in pregnancy-related care.

4.3 Antibody screening

Antibody screening detects unexpected antibodies directed against red cell antigens. These antibodies may arise after prior transfusion or pregnancy. Identifying them helps prevent incompatible transfusion and guides selection of suitable donor units.

4.4 Crossmatching

Crossmatching is a compatibility test in which donor red cells are tested against recipient plasma. It confirms that no clinically significant reaction is likely before transfusion proceeds. Crossmatching may be more or less extensive depending on the patient’s history and the laboratory method used.

4.5 Pretransfusion testing

Pretransfusion testing usually includes patient identification, blood typing, antibody screening, and review of previous records. Additional tests may be required in complex cases, such as those with multiple antibodies or a history of transfusion reactions. The goal is to ensure that the correct product is issued for the correct patient.

5 Donation and collection

Blood donation supplies the material used for transfusion therapy. Collection systems are designed to protect donors, ensure product quality, and maintain sterility. The process includes donor assessment, collection, component preparation, and storage under controlled conditions.

5.1 Blood donation types

Donation may involve whole blood collection or donation of a specific component. Whole blood donation is the most common method in many regions, while component donation allows collection of platelets or plasma by machine. Each type of donation serves different clinical needs.

5.2 Donor eligibility

Donor eligibility is based on health status, age or weight criteria, medical history, travel history, and risk factors for infection or adverse donation reactions. Screening aims to protect both donor and recipient. Individuals who do not meet criteria may be deferred temporarily or permanently.

5.3 Apheresis collection

Apheresis is a method in which blood is withdrawn, a desired component is separated by machine, and the remaining elements are returned to the donor. It is commonly used to collect platelets, plasma, or selected red cell products. This technique can yield larger amounts of a single component than whole blood donation.

5.4 Blood component preparation

After collection, blood may be separated into components by centrifugation and processing. This allows a single donation to be divided into red blood cells, plasma, platelets, or other products. Preparation also includes labeling, testing, and quality checks before release for clinical use.

5.5 Storage and shelf life

Blood components have different storage requirements and expiration periods. Red blood cells are refrigerated, platelets are stored at controlled room temperature with agitation, and plasma is frozen until use. Shelf life is limited by factors such as cell viability, clotting factor stability, and bacterial growth risk.

6 Administration

Safe transfusion depends not only on selecting the right product but also on careful administration at the bedside. Errors in identification or handling can cause serious harm. Standard procedures are designed to confirm the intended recipient, deliver the product properly, and detect reactions early.

6.1 Patient identification

Correct patient identification is fundamental before transfusion begins. Staff typically verify the patient using multiple identifiers and match them with the blood unit and laboratory documentation. This step is intended to prevent wrong-patient or wrong-product transfusion.

6.2 Intravenous access

Blood products are administered through suitable intravenous access. The line must permit safe infusion and should be checked for patency before use. When multiple products or rapid transfusion are needed, larger-bore access or specialized equipment may be required.

6.3 Transfusion rates

The rate of infusion depends on the patient’s condition, the type of product, and the clinical setting. Emergency transfusions may be given rapidly, while routine administration is usually slower. Rate selection balances the need for prompt treatment with the risk of fluid overload and other complications.

6.4 Monitoring during transfusion

Patients are observed for signs of reaction during and after transfusion. Monitoring may include vital signs, symptoms such as fever or rash, and changes in respiratory or hemodynamic status. Early recognition of problems allows prompt discontinuation of the transfusion and treatment of the reaction.

6.5 Documentation and traceability

Detailed documentation records the product type, donor information, unit number, transfusion time, and any adverse events. Traceability is necessary to track each blood component from donor to recipient. This system supports investigation of reactions, quality control, and regulatory compliance.

7 Risks and complications

Although transfusion is generally safe when properly performed, complications can occur. Some are immediate, while others appear days or weeks later. The likelihood and severity of complications vary according to the product, the recipient’s condition, and the accuracy of compatibility testing.

7.1 Acute transfusion reactions

Acute reactions occur during or shortly after transfusion. They may present with fever, chills, rash, dyspnea, pain, hypotension, or other nonspecific symptoms. Prompt evaluation is important because some reactions are mild while others are life-threatening.

7.1.1 Febrile non-hemolytic reactions

Febrile non-hemolytic reactions are characterized by a temperature rise and sometimes chills. They are usually caused by cytokines or recipient response to donor leukocytes. These reactions are generally not dangerous but may require stopping the transfusion and assessing the patient.

7.1.2 Allergic reactions

Allergic reactions range from mild urticaria and itching to more severe systemic symptoms. They are often related to plasma proteins in the transfused component. Mild reactions may be managed symptomatically, while significant reactions require immediate evaluation and treatment.

7.1.3 Hemolytic reactions

Hemolytic reactions occur when transfused red cells are destroyed, often because of incompatibility. They may be acute and severe, with fever, pain, hypotension, hemoglobinuria, and shock. Rapid recognition is essential because these reactions can become fatal if transfusion continues.

7.2 Delayed complications

Delayed complications may include delayed hemolytic reactions, alloimmunization, and transfusion-related changes that become apparent after the procedure. Such events can complicate future transfusions and make antibody identification more difficult. Some delayed effects are discovered only through follow-up testing.

7.3 Infectious risks

Transfusion can transmit infectious agents if screening or processing fails, although modern safeguards have made this uncommon in many settings. Risk reduction relies on donor screening, laboratory testing, and product handling measures. Residual risk remains a recognized concern in blood safety systems.

7.4 Iron overload

Repeated transfusions can lead to accumulation of iron, since the body has limited means to remove excess iron from transfused red cells. Iron overload may damage organs over time, particularly in patients who require chronic transfusion. Chelation therapy is sometimes used to reduce iron burden.

7.5 Transfusion-associated circulatory overload

Transfusion-associated circulatory overload results from excessive volume or infusion rate relative to the patient’s cardiovascular reserve. It can cause respiratory distress, hypertension, and pulmonary edema. Patients at increased risk include those with heart failure, kidney impairment, or very small body size.

Transfusion-related acute lung injury is a serious respiratory complication marked by acute hypoxemia and noncardiogenic pulmonary edema. It typically develops soon after transfusion and requires urgent supportive care. Recognition is important because the syndrome can resemble other forms of respiratory failure.

8 Special populations

Certain groups have distinct transfusion needs because of age, physiologic state, or underlying disease. In these patients, product selection, dose, and monitoring may differ from standard adult practice. Individualized protocols improve safety and effectiveness.

8.1 Neonates and children

Infants and children require age-appropriate dosing and careful attention to volume. Neonatal transfusion may involve smaller aliquots, modified products, and specific compatibility practices. Because circulating blood volume is limited, even small administration errors can have significant consequences.

8.2 Pregnancy and obstetric care

Transfusion in pregnancy and childbirth may be needed for bleeding, anemia, or coagulation problems. Compatibility issues are especially important because red cell antibodies can affect both mother and fetus. Obstetric transfusion planning often includes preparation for rapid blood replacement when hemorrhage is anticipated.

8.3 Patients with chronic transfusion needs

Some patients receive repeated transfusions for long-term conditions such as inherited anemias or marrow failure syndromes. These individuals are at greater risk of alloimmunization, iron overload, and cumulative exposure to donor products. Long-term management often includes specialized matching and regular monitoring.

8.4 Immunocompromised patients

Immunocompromised patients may need modified blood products to reduce complications. They can be more vulnerable to infection, transfusion-associated immune effects, or reactions related to donor white cells. Product selection and processing may be adjusted according to the clinical context.

9 Alternatives and blood conservation

Because transfusion carries risks and depends on a limited resource, alternatives are often used when appropriate. Blood conservation strategies reduce the need for donor blood by improving erythropoiesis, minimizing loss, or recovering blood during procedures. These approaches are particularly valuable in planned care.

9.1 Iron therapy and hematinic treatment

Iron, vitamin B12, and folate supplementation can correct deficiencies that contribute to anemia. Treating the underlying deficiency may reduce or eliminate the need for transfusion. This approach is most effective when anemia develops gradually and there is time for blood counts to recover.

9.2 Erythropoiesis-stimulating agents

Erythropoiesis-stimulating agents promote red blood cell production in selected patients with chronic anemia. They are used in specific conditions where the marrow can respond adequately and where transfusion avoidance is desirable. Their role depends on the diagnosis and risk-benefit assessment.

9.3 Autologous blood strategies

Autologous strategies use the patient’s own blood rather than donor blood. These may include preoperative donation in selected situations or planned recovery methods during surgery. Their use has decreased in some settings but remains relevant in certain elective procedures.

9.4 Cell salvage

Cell salvage collects blood lost during surgery, processes it, and returns it to the patient. It can reduce exposure to donor blood and is especially useful when substantial blood loss is expected. The technique requires specialized equipment and appropriate case selection.

9.5 Restrictive transfusion strategies

Restrictive transfusion strategies aim to transfuse only when clinically necessary and at lower hemoglobin thresholds than in more liberal practice. These protocols are based on evidence that many patients do well with fewer transfusions. They help conserve blood resources and may reduce exposure-related complications.

10 Regulation and safety

Transfusion systems depend on oversight, standard procedures, and continuous quality improvement. Regulation addresses the collection, testing, storage, distribution, and administration of blood products. Safety programs are designed to prevent error and to identify problems quickly when they occur.

10.1 Blood bank standards

Blood bank standards define requirements for testing, labeling, storage, and compatibility procedures. They also cover staff competence, equipment maintenance, and record keeping. Standardization helps ensure that blood products are prepared and released consistently and safely.

10.2 Product labeling and storage rules

Labels on blood products provide essential information, including component type, blood group data, expiration, and special processing. Storage rules specify temperature, handling, and transport conditions for each product. Proper labeling and storage are necessary to preserve quality and prevent misuse.

10.3 Hemovigilance

Hemovigilance is the systematic monitoring of transfusion-related adverse events. It includes reporting, investigation, and analysis of reactions and near misses. The goal is to identify patterns, improve practice, and reduce preventable harm.

10.4 Quality assurance and auditing

Quality assurance programs assess whether transfusion services meet required standards and whether procedures are being followed correctly. Auditing may examine sample labeling, reaction reporting, inventory management, and documentation practices. Findings are used to improve performance, retrain staff, and strengthen patient safety.